Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Han Lee

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Statistics in Medicine|June 10, 2025
Multiple Imputation Confidence Intervals for a Risk Difference With Missing ObservationsChung-Han Lee
Expert Review of Anticancer Therapy|September 26, 2022
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinomaYasser Ged, Chung-Han Lee
JAMA Oncology|December 28, 2018
Treatment of Metastatic Prostate Cancer in 2018Chung-Han Lee, Philip Kantoff
Statistics in Medicine|November 17, 2021
Multiple imputation confidence intervals for the mean of the discrete distributions for incomplete dataChung-Han Lee, Hsiuying Wang
British Journal of Cancer|October 18, 2018
Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinomaChung-Han Lee, Robert Motzer
Nature Reviews. Urology|December 13, 2018
Combination therapy for advanced and metastatic kidney cancerChung-Han Lee, Robert J Motzer
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2022
Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic OptionsKelly N Fitzgerald, Chung-Han Lee
Journal of Breast Cancer|April 12, 2012
Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast CancerDong Won Ryu, Chung Han Lee
Journal of the Korean Surgical Society|October 24, 2012
Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell deathDong Won Ryu, Chung Han Lee
Cancer Journal (Sudbury, Mass.)|April 26, 2016
Immune Checkpoint Therapy in Renal Cell CarcinomaChung-Han Lee, Robert J Motzer
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Statistics in Medicine|June 10, 2025
Multiple Imputation Confidence Intervals for a Risk Difference With Missing ObservationsChung-Han Lee
Expert Review of Anticancer Therapy|September 26, 2022
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinomaYasser Ged, Chung-Han Lee
JAMA Oncology|December 28, 2018
Treatment of Metastatic Prostate Cancer in 2018Chung-Han Lee, Philip Kantoff
Statistics in Medicine|November 17, 2021
Multiple imputation confidence intervals for the mean of the discrete distributions for incomplete dataChung-Han Lee, Hsiuying Wang
British Journal of Cancer|October 18, 2018
Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinomaChung-Han Lee, Robert Motzer
Nature Reviews. Urology|December 13, 2018
Combination therapy for advanced and metastatic kidney cancerChung-Han Lee, Robert J Motzer
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2022
Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic OptionsKelly N Fitzgerald, Chung-Han Lee
Journal of Breast Cancer|April 12, 2012
Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast CancerDong Won Ryu, Chung Han Lee
Journal of the Korean Surgical Society|October 24, 2012
Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell deathDong Won Ryu, Chung Han Lee
Cancer Journal (Sudbury, Mass.)|April 26, 2016
Immune Checkpoint Therapy in Renal Cell CarcinomaChung-Han Lee, Robert J Motzer
Pageof 11